Abstract:In this article, we discuss nasal mucosal immunity against SARS‐CoV‐2, the nasal cavity being an important body part that protects against the virus. Immunisation of the nasal mucosa produces immunoglobulin A antibodies that effectively neutralise viruses. Intranasal vaccine can make up for the deficiency of intramuscular vaccine in inducing nasal mucosal immunity and has a broad application prospect in the prevention and resistance of SARS‐CoV‐2. Coronavirus disease 2019, caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has affected 700 million people worldwide since its outbreak in 2019. The current pandemic strains, including Omicron and its large subvariant series, exhibit strong transmission and stealth. After entering the human body, the virus first infects nasal epithelial cells and invades host cells through the angiotensin‐converting enzyme 2 receptor and transmembrane serine protease 2 on the host cell surface. The nasal cavity is an important body part that protects against the virus. Immunisation of the nasal mucosa produces immunoglobulin A antibodies that effectively neutralise viruses. Saline nasal irrigation, a type of physical therapy, can reduce the viral load in the nasal cavity and prevent viral infections to some extent. As a commonly used means to fight SARS‐CoV‐2, the intramuscular (IM) vaccine can induce the human body to produce a systemic immune response and immunoglobulin G antibody; however, the antibody is difficult to distribute to the nasal mucosa in time and cannot achieve a good preventive effect. Intranasal (IN) vaccines compensate for the shortcomings of IM vaccines, induce mucosal immune responses, and have a better effect in preventing infection. In this review, we discuss the nasal defence barrier, the harm caused by SARS‐CoV‐2, the mechanism of its invasion into host cells, nasal cleaning, IM vaccines and IN vaccines, and suggest increasing the development of IN vaccines, and use of IN vaccines as a supplement to IM vaccines.

Review: The Nose as a Route for Therapy. Part 2 Immunotherapy

Olfactory immunology: the missing piece in airway and CNS defence

Upper Airway Stem Cells: Understanding the Nose and Role for Future Cell Therapy

The Microbiota/Host Immune System Interaction in the Nose to Protect from COVID-19

The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection

Advances in intranasal vaccine delivery: A promising non-invasive route of immunization

Nasal microbiome dynamics: decoding the intricate nexus in the progression of respiratory and neurological diseases

Mucosal Immunity against SARS-CoV-2 in the Respiratory Tract

Intranasal COVID-19 Vaccines: from Bench to Bed

Potentiating Lung Mucosal Immunity Through Intranasal Vaccination

From intramuscular to nasal: unleashing the potential of nasal spray vaccines against coronavirus disease 2019

Improving Nasal Protection for Preventing SARS-CoV-2 Infection

Investigating Experimental Treatments for Rhinitis: A State-of-the-Art Systematic Review

Tailoring Formulations for Intranasal Nose-to-Brain Delivery: A Review on Architecture, Physico-Chemical Characteristics and Mucociliary Clearance of the Nasal Olfactory Mucosa

Recent advances in improving intranasal allergen-specific immunotherapy; focus on delivery systems and adjuvants

Increased nasal mucosal interferon and CCL13 response to a TLR7/8 agonist in asthma and allergic rhinitis

Nitric Oxide and its Derivatives Containing Nasal Spray and Inhalation Therapy for the Treatment of COVID-19

Type 2 and Non-type 2 Inflammation in the Upper Airways: Cellular and Molecular Alterations in Olfactory Neuroepithelium Cell Populations

Immunoregulatory Nanomedicine for Respiratory Infections

Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract